Trials / Completed
CompletedNCT04709536
A Study of IBI306 in Participants With Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of IBI306 in Patients With Hypercholesterolemia in China (CREDIT-4)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 306 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed for multi-center, double-blind, randomized, placebo-controlled phase III trial to evaluate the safety and tolerability of subcutaneous injection of IBI306 in hypercholesterolemia patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI306 | Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24 |
| DRUG | Placebo | Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24 |
Timeline
- Start date
- 2021-02-09
- Primary completion
- 2021-11-09
- Completion
- 2022-01-28
- First posted
- 2021-01-14
- Last updated
- 2024-10-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04709536. Inclusion in this directory is not an endorsement.